Assessing the Reporting of Harms in Systematic Reviews Focused on the Therapeutic and Cosmetic Uses of Botulinum Toxin.

Katherine Cox Merhawit Ghebrehiwet Micah Kee Brayden M Rucker Holly Flores Ryan Ottwell Matt Vassar

Published in: Clinical drug investigation (2023)

Our results demonstrate that harms are underreported within BoNT SRs. Because healthcare professionals often refer to SRs to guide clinical decision making, it is important to continue to explore shortcomings among BoNT literature in future studies.

Keyphrases

botulinum toxin
systematic review
decision making
current status
adverse drug
meta analyses
case control
randomized controlled trial
emergency department